Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Pepgen
company
About
PepGen is empowering nucleic acid therapeutics to go the distance.
- 1 - 10
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $112.50M
- Industries
- Biotechnology,Clinical Trials,Medical
- Founded date
- Jan 1, 2018
- Number Of Employee
- 1 - 10
- Operating Status
- Active
PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and they are advancing novel conjugate therapeutics to the clinic.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$157.50M
Pepgen has raised a total of
$157.50M
in funding over 2 rounds. Their latest funding was raised on
Aug 5, 2021 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 5, 2021 | Series Unknown | $112.50M | 1 | — | — | Detail |
| Dec 9, 2020 | Series A | $45M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Pepgen is funded by 1 investors.
CureDuchenne Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
CureDuchenne Ventures
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
